Compare Recursion Pharmaceuticals Inc (RXRX) vs Solaris Energy Infrastructure Inc. Class A Common Stock (SEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Solaris Energy Infrastructure Inc. Class A Common Stock — how do they compare? Recursion Pharmaceuticals Inc trades at $3.66 (market cap $2.08B), while Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.5 (market cap $5.12B). The key difference: Solaris Energy Infrastructure Inc. Class A Common Stock is far larger — about 2.5× Recursion Pharmaceuticals Inc's market cap, and Solaris Energy Infrastructure Inc. Class A Common Stock pays a 0.62% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days on average.
| RXRX | SEI | |
|---|---|---|
Market Cap | $2.08B | $5.12B |
Volume | 19,700,033 | 2,532,496 |
Sector | Health | Energy |
52-Week High | $6.79 | $82.88 |
52-Week Low | $2.84 | $40.64 |
Typical Hold Time | 22 Days | 0 Days |
Enterprise Value | $1.60B | $6.81B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.835, down 4.36% today, with technical indicators showing a bullish trend despite recent weakness. The company reported revenue of $74.26M in 2025 but posted a significant net loss of -$644.76M, reflecting negative profit margins. Recent news highlights strategic AI partnerships and pipeline expansion, though the stock faces high short interest and ongoing operational losses.
Outlook remains speculative with 40% analyst buy ratings but substantial financial losses. Key opportunities include AI-driven drug discovery partnerships, while risks involve cash burn, competitive pressures, and delayed profitability. The stock's valuation at 36.1x sales appears stretched given current financial performance.
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Solaris Energy Infrastructure Inc. Class A Common Stock
Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →
